New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL)...

Related Keywords

Paris ,France General ,France ,California ,United States ,San Diego ,American ,Catherine Thieblemont ,Hematol Hemoter ,Mariana Cota Stirner ,Data From The Observational National Lymphocare Study ,Lymphoma Research Foundation ,European Medicines Agency ,Facebook ,Drug Administration ,Us Inc ,Exchange Commission ,American Society Of Hematology ,European Union ,Paris University ,Linkedin ,Twitter ,Instagram ,Youtube ,American Society ,Saint Louis Assistance Publique Hopitaux De Paris ,Breakthrough Therapy Designation ,Follicular Lymphoma ,Release Syndrome ,Full Prescribing Information ,Medication Guide ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Research Foundation ,Opin Med ,Bras Hematol ,Subsequent Therapy ,Data From ,Observational National Lymphocare ,Treatment Patterns ,Patients With Diffuse Largeb Cell Lymphoma ,